Capsid and Tail

a weekly phage periodical
Issue Two: Clinical Trials
October 26, 2018

Clinical trials: Are phages “there yet”?

You may have heard that phages "still haven’t made it through clinical trials.” What does this mean, and is anyone making any progress on this?

But First...

Dr. Urmi Bajpai invited phage researchers to join a newly unveiled global research consortium for promoting phage and lysin therapy: the International Bacteriophage Research Consortium. This is a collaboration between Acharya Narendra Dev College (University of Delhi, India) and Open Health Systems Laboratory (USA). Join the consortium here!

News

Chen et al. published a groundbreaking new study on the discovery of a new kind of phage transduction that leads to genome hypermobility. You’ve heard of generalized and specialized transduction—now there’s “lateral transduction.”

NewsResearch

Dr. Darren Smith posted a new 24-month postdoc position at Northumbria University in Newcastle upon Tyne, UK. The postdoc will study the ecology and biology of phages in the guts of pre-term infants. Apply by Nov 30, 2018.

Jobs

Eric Boodman wrote a great article on the background of Adaptive Phage Therapeutics (paywall)

News

No new jobs this week. If you’d like to add one, please post one by emailing [email protected]

Community Board

Have a question or request for the phage community? Post it here and reach > 200 phage enthusiasts spanning academia, industry, medicine, and beyond. Feel free to be creative about what you might ask! (e.g. collaborations, advice, seeking opportunities)

The community board is empty this week. Be the first to post something for next week!

Clinical trials: Are phages “there yet”?

You may have heard that phages "still haven’t made it through clinical trials.” What does this mean, and is anyone making any progress on this?

Do you have experience with or knowledge of clinical trials? If you have anything to add, please let us know on our feedback page.

We’d love to hear from you!

Are they toxic? Do they work?

To sell a phage as a drug in the US, you need to show the FDA that it’s safe in humans and that it works better than whatever’s already on the market to treat the condition you’re trying to treat. The European Medicines Agency (EMA) regulates drugs similarly in Europe.

Phase I, II, III… what?

You may have heard about phase I, II and III clinical trials. What do these mean? Put simply, phase I trials involve testing the drug on people to see if the drug is safe. Phase II trials involve testing for efficacy and looking for side-effects (usually 100-300 patients). Phase III trials are similar, but involve a lot more patients (usually 300-3000).

Are phages there yet?

Several research groups and companies around the world have completed phase I trials to show that phages are safe in humans. As well, many phage therapy case studies and case series have been done to evaluate phage efficacy. However, although case studies and case series can inform the design of randomized, controlled clinical trials, they do not replace them. Only a few randomized, controlled phase II clinical trials have been completed with phages, and those that have been completed have shown mixed outcomes.

In 2009, a small (24 patients) randomized, controlled phase II clinical trial in the UK showed that phages improved P. aeruginosa-induced ear infections. On the other hand, other randomized, controlled phase II phage trials have had things go wrong.

Are we learning anything?

We can learn a lot about how to do phage trials by scrutinizing the trials that didn’t show phage efficacy. For example, in 2013, a phase II trial was done to test the efficacy of E. coli phages on diarrhea in children, but the phages didn’t get rid of the diarrhea. However, it was later found that the diarrhea probably wasn’t caused by E. coli, so the fact that the E. coli phages didn’t help isn’t surprising. This trial emphasized the importance of pre-identifying the disease-causing organism before treating with phages.

As recently as this year, a phase II trial to test phage treatment of P. aeruginosa-infected burn wounds, known as PhagoBurn, was completed in France, Belgium and Switzerland by the French company Pherecydes Pharma. Unfortunately, this trial showed that phages were less effective than the standard of care for burn patients. However, the company admitted that mixing their phages in a cocktail actually inactivated most of their phages, so patients ended up getting far fewer phages than they were meant to. The surprising part is that this low-level phage treatment actually did help the patients. This trial underscored the importance of understanding the conditions that inactivate or destabilize a given phage before using it for therapy.

What will 2019 bring?

Looking forward, 2019 could be one of the biggest years yet for randomized, controlled clinical trials that look for phage efficacy. For instance, Ampliphi will be doing phase II phage trials to treat Staphylococcus aureus-induced bacteremia and prosthetic joint infections and P. aeruginosa-induced pneumonia and bacteremia. Intralytix will be doing phase II phage trials to treat adhesive invasive E. coli (AIEC) infections in inflammatory bowel disease patients. Adaptive Phage Therapeutics will be testing its phages on UTIs in children (paywall).

Large, controlled, randomized efficacy trials cost a lot more than small safety trials, so it’s a big deal that companies are making these investments. The bottom line is that it’s becoming clear that phages are safe and that they’re probably effective at treating infections—now it’s likely just a matter of getting the conditions right.

Thanks for reading! Next week, we’ll cover phage treatments that are done outside of traditional clinical trials—who’s getting treated and how does this work?

~ Jessica
<>={

Jessica Sacher is a co-founder of Phage Directory and has a Ph.D in Microbiology and Biotechnology.

Stay updated on phage research, phage therapy, and phage jobs by getting Capsid & Tail every week!

Have an idea for a story, news to share, or wanting to write an opinion piece? Get in touch at [email protected] or tweet @phagedirectory

For every issue of Capsid & Tail, we are committed to getting our facts straight, but we’re not experts in the information we’re bringing to you. If you feel that we’ve missed an important viewpoint, or if you have something to add, please reach out to us by emailing [email protected]. We’d love to hear from you, and we’d be happy to revisit topics we’ve covered (ideally with added information and viewpoints from community members like you!).

Lastly, please reach out if you’re interested in writing for us, or have suggestions for future issues!